ArticleBMC medical imaging2026
Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeIdentifying the stratification expression of Ki67 is crucial for directing clinical treatment strategies in ER+/HER2- breast cancers. This diagnostic study investigated the value of first-order features extracted from conventional DWI, diffusion kurtosis imaging (DKI), fractional order calculus (FROC), and continuous-time random walk (CTRW) in discriminating Ki67 expression of ER+/HER2- invasive ductal breast cancer. MATERIALS AND
methodsThis retrospective study included 121 patients who underwent DWI, DKI, FROC and CTRW and were pathologically categorized into the low (≤ 5%, n = 30), medium (> 5% to < 30%, n = 41), and high Ki67 expression group (≥ 30%, n = 50). Sixty-three diffusion parameters were computed and subsequently compared across different groups. The area under the receiver operating characteristic (ROC) curve (AUC) was used to quantify diagnostic efficacy. Multivariate logistic regression and bootstrap (1,000 samples) analyses were used to establish and evaluate, respectively, the optimal model to identify Ki67 expression.
resultsTwenty-three features showed statistically significant differences among the low, medium and high expression groups (all p values < 0.05). Further multivariable logistic regression analysis for discriminating the low Ki67 and non-low expression group showed that the FROC model constructed by D
conclusionsThe FROC model could help identify the low Ki67 expression (≤ 5%) and prevent unnecessary chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.